Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Krakow
Clinical trial register · Poland

Clinical Trials in Krakow, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2705 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC
2705
Studies in scope
all four open statuses
1389
Recruiting now
open to new participants
512
Lead sponsors
across recruiting studies
Top sites
Warsaw 44 Bydgoszcz 42 Lublin 36 Krakow 36 Gdansk 30
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca70 Hoffmann-La Roche42 Eli Lilly and Company38 Merck Sharp & Dohme LLC36 Janssen Research & Development, LLC36 Clear sponsor filter
Site location
Warsaw44 Bydgoszcz42 Lublin36 Krakow36 Gdansk30
All 60 locations
Target enrolment
to

Trials with a site in Krakow

36 of 2705 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Bydgoszcz, Krakow, Lublin, Olsztyn, Opole, Rzeszów, Szczecin, Torun
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Bydgoszcz, Krakow, Lublin, Olsztyn, Opole, Rzeszów, Szczecin, Torun
2026-05-22
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Bydgoszcz, Krakow, Rzeszów, Szczecin, Torun, Warsaw
2026-04-21
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Bydgoszcz, Bytom, Katowice, Krakow, Nadarzyn, Nowa Sól, Poznan, Płońsk
2026-03-05
Active, closed
Janssen Research & Development, LLC
Phase 2
168
Brzozów, Kielce, Krakow, Lodz, Lublin, Poznan, Torun, Wroclaw
2026-02-08
Recruiting
Janssen Research & Development, LLC
Phase 2
240
Bialystok, Bydgoszcz, Elblag, Krakow, Lublin, Nadarzyn, Olsztyn, Torun
2026-01-15
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Bydgoszcz, Krakow, Lublin, Nowy Targ, Olsztyn, Opole, Poznan, Rzeszów
2025-10-03
Recruiting
Janssen Research & Development, LLC
Phase 3
882
Bydgoszcz, Katowice, Krakow, Lublin, Nowy Targ, Olsztyn, Opole, Poznan
2025-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
752
Bialystok, Elblag, Katowice, Krakow, Lodz, Olsztyn, Poznan, Skierniewice
2025-04-15
Active, closed
Janssen Research & Development, LLC
Phase 3
552
Bialystok, Bydgoszcz, Elblag, Gdynia, Krakow, Lodz, Lublin, Nadarzyn
2025-02-21
Recruiting
Janssen Research & Development, LLC
Phase 3
750
Bialystok, Bydgoszcz, Elblag, Gdynia, Krakow, Lodz, Lublin, Nadarzyn
2025-01-09
By invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543·Ibrutinib
Janssen Research & Development, LLC
Phase 1
120
Gdansk, Krakow, Skorzewo
2024-12-30
Active, closed
Janssen Research & Development, LLC
Phase 3
655
Bydgoszcz, Dębica, Krakow, Lublin, Olsztyn, Poznan, Siedlce, Warsaw
2024-12-04
Active, closed
Janssen Research & Development, LLC
Phase 2
333
Biała Podlaska, Brzozów, Gdynia, Kielce, Krakow, Lodz, Lublin
2024-05-30
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Bialystok, Bydgoszcz, Krakow, Lublin, Przemyśl, Tarnów, Torun, Wieliszew
2024-04-09
Active, closed
Janssen Research & Development, LLC
Phase 3
731
Bialystok, Katowice, Kielce, Krakow, Olsztyn, Warsaw, Wroclaw
2024-03-09
Active, closed
Janssen Research & Development, LLC
Phase 3
774
Bialystok, Elblag, Krakow, Lodz, Osielsko, Poznan, Warsaw, Wroclaw
2024-01-17
Active, closed
Janssen Research & Development, LLC
Phase 3
311
Bialystok, Krakow, Lodz, Osielsko, Poznan, Warsaw, Wroclaw
2023-10-12
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Bialystok, Elblag, Krakow, Lodz, Osielsko, Poznan, Warsaw, Wroclaw
2023-10-12
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Brzozów, Gdansk, Katowice, Kielce, Krakow, Lublin, Olsztyn, Szczecin
2022-10-13
Recruiting
Janssen Research & Development, LLC
Phase 2/3
201
Chorzów, Krakow, Lublin, Poznan
2022-09-23
Active, closed
Janssen Research & Development, LLC
Phase 2
577
Bydgoszcz, Krakow, Lodz, Lublin, Nowy Targ, Olsztyn, Poznan, Rzeszów
2022-09-19
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Bialystok, Bydgoszcz, Chojnice, Krakow, Lublin, Poznan, Rzeszów, Szczecin
2022-09-13
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Bydgoszcz, Krakow, Otwock, Poznan, Warsaw
2022-08-05
Active, closed
Janssen Research & Development, LLC
Phase 2
703
Bydgoszcz, Krakow, Lodz, Lublin, Olsztyn, Poznan, Rzeszów, Sopot
2022-07-22
Active, closed
Janssen Research & Development, LLC
Phase 3
350
Bialystok, Bydgoszcz, Chojnice, Chrzanów, Knurów, Krakow, Lodz, Lublin
2022-01-19
Active, closed
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
DrugUstekinumab
Janssen Research & Development, LLC
Phase 3
159
Krakow, Rzeszów, Sosnowiec, Torun, Warsaw
2021-10-18
Active, closed
Janssen Research & Development, LLC
Phase 4
411
Bialystok, Bydgoszcz, Bytom, Elblag, Krakow, Lodz, Lublin, Nadarzyn
2021-08-30
Recruiting
Janssen Research & Development, LLC
Phase 3
199
Bydgoszcz, Katowice, Krakow, Lublin, Warsaw
2021-07-15
Active, closed
Janssen Research & Development, LLC
Phase 3
1,054
Bialystok, Bydgoszcz, Elblag, Gdynia, Krakow, Lublin, Nadarzyn, Nowa Sól
2021-06-17
Active, closed
Janssen Research & Development, LLC
Phase 3
696
Bydgoszcz, Gdynia, Konin, Krakow, Lodz, Lublin, Siedlce, Warsaw
2020-09-23
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
Bialystok, Bydgoszcz, Krakow, Lublin, Oświęcim, Rzeszów, Sopot, Szczecin
2019-09-26
Active, closed
Janssen Research & Development, LLC
Phase 3
2,517
Bydgoszcz, Koszalin, Krakow, Warsaw, Wroclaw
2019-06-11
Active, closed
Janssen Research & Development, LLC
Phase 3
84
Bydgoszcz, Gdansk, Krakow, Olsztyn, Rzeszów, Warsaw
2018-10-29
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Bydgoszcz, Chojnice, Częstochowa, Gdansk, Gdynia, Jelenia Góra, Katowice, Krakow
2018-04-13
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
539
Brzozów, Chorzów, Gdansk, Klinika Nowotworow Ukladu Chlonnego, Krakow, Opole, Słupsk, Wroclaw
2013-09-09
Rows per page Showing 1–36 of 36
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 October 2026. https://priyalifescience.com/clinical-trials-poland/city/krakow

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,705 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 36 of those studies with a site in Krakow that also match the filters currently applied.

How many clinical trials are recruiting in Krakow?

10 of the 36 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 25 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Krakow), 36 studies
PhaseStudiesRecruitingShare
Phase 325769.4%
Phase 25113.9%
Phase 2/34211.1%
Phase 1102.8%
Phase 4102.8%

Most active sponsors

Lead sponsors with the most studies (Krakow)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC3610
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.